Skip to main content
. 2022 Dec 15;25(4):131–138. doi: 10.7602/jmis.2022.25.4.131

Table 2.

Treatment, operative, and postoperative characteristics

Characteristic Data (n = 124)
Preoperative radiation
No 8 (6.5)
Long course chemoradiation 84 (67.7)
Short course chemotherapy 33 (26.6)
Preoperative chemotherapy 66 (53.2)
Surgery
Total pelvic exenteration 74 (59.7)
Posterior exenteration 36 (29.0)
Bladder sparing exenteration 14 (11.3)
Surgical approach
Laparoscopic 95 (76.6)
Robotic 29 (23.4)
Sphincter preservation 36 (29.0)
Lateral pelvic node dissection 70 (56.5)
Urinary reconstruction
Ileal conduit 72 (58.1)
Sigmoid conduit 4 (3.2)
Supra-pubic catheter 14 (11.3)
Ureteric reimplantation 1 (0.8)
Not applicable 47 (37.9)
Perineal reconstruction (n = 95) 66 (69.5)
Sacrectomy 5 (4.0)
Surgical duration (min) 520 (420–650)
Blood loss (mL) 700 (480–1,300)
Hospital stay (mL) 11 (8–15)
Clavien-Dindo complications
0 48 (38.7)
I 12 (9.7)
II 29 (23.4)
IIIA 14 (11.3)
IIIB 17 (13.7)
IV 1 (0.8)
V 3 (2.4)
Complications, ASA PS grade ≥IIIA; 95% CI 35 (28.2); 20.5%–37.0%
Leak
Urinary (n = 91) 13 (14.3)
Bowel (n = 36) 5 (13.9)
Surgical site infection 27 (21.8)
Small bowel obstruction 13 (10.5)

Values are presented as number (%) and median range unless otherwise specified.

ASA PS, American Society of Anesthesiologist physical status; CI, confidence interval.